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Abstract
big-h3 (TGFBI, keratoepithelin) was first identified as a transforming growth factor-h1 (TGF-h1)-inducible gene in a human lung
adenocarcinoma cell line. It encodes for a secreted extracellular matrix (ECM) protein, which is thought to act on cell attachment and ECM
composition. Mutations of the big-h3 gene are involved in several corneal dystrophies. Pancreatic cancers display multiple alterations in the
TGF-h signaling pathway and in TGF-h response genes, such as overexpression of all three TGF-h isoforms and Smad4mutations. In this report,
we determined that big-h3mRNA levels were induced byTGF-h1 in two out of five examined pancreatic cancer cell lines (CAPAN-1, PANC-1).
In CAPAN-1 cells, which harbor a Smad4 mutation, big-h3 but not PAI-1 was induced by TGF-h1, whereas in PANC-1 cells that express wild-
type Smad4, TGF-h1 induced both PAI-1 and big-h3. In human pancreatic tissues, there was a 32.4-fold increase in big-h3 mRNA levels in
pancreatic cancers in comparison to normal control tissues. In situ hybridization analysis revealed that big-h3mRNAwas expressedmainly in the
cancer cells within the pancreatic tumor mass. These findings suggest that big-h3 is induced by TGF-hs in pancreatic cancer cells even in the
presence of Smad4 mutations, which might explain, in part, the increased big-h3 mRNA levels observed in pancreatic cancer cells in vivo.
D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
big-h3 (TGFBI, keratoepithelin) is a gene that was first
discovered by differential expression analysis of a trans-
forming growth factor-h1 (TGF-h1)-treated human lung
adenocarcinoma cell line [1]. It encodes a 68-kDa protein
with an amino-terminal secretory sequence and a carboxy
terminal sequence that can serve as a ligand recognition
site for several integrins [1]. Subsequent analysis revealed
that big-h3 is strongly induced by TGF-h1 in several cell
lines, including human melanoma cells, human mammary
epithelial cells, human keratinocytes, and human fibro-
blasts [2,3]. Expression of big-h3 has also been observed
in corneal epithelial cells [4], skin fibroblasts [2], endo-
thelial cells [5], in the juxtaglomerular apparatus and the
pars recta of the proximal tubules in the kidney [6], in
bladder smooth muscle cells, and in bladder urothelium
[7].
Further functional analysis has revealed that big-h3 is
secreted into the extracellular matrix (ECM), and that it may
function as an extracellular attachment protein, thus influ-
encing cell attachment and migration [2]. These initial
results led to further investigations regarding the role of
big-h3 in human diseases. For example, in coronary heart
disease, restenotic coronary lesions showed high levels of
big-h3 in areas of dense fibrous connective tissue. big-h3
was present in the cytoplasm of plaque macrophages as well
as smooth muscle and endothelial cells. [5]. Most of the
research has focused on the role of big-h3 in corneal
dystrophy [8]. Thus, big-h3 mutations have been detected
in six different autosomal dominant corneal dystrophies,
such as Fuchs’ dystrophy, Avellino corneal dystrophy,
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Sardinian Reis Bucklers corneal dystrophy, and others, and
the excessive big-h3 content in these corneas suggests that
the mutated gene product is a fundamental constituent of the
characteristic corneal accumulations [8–14].
Our current knowledge of the potential role of big-h3 in
malignant processes is limited to data from cultured cell
lines. For example, SV40-transformed human fibroblasts
exhibit down-regulation of big-h3 expression in comparison
to normal fibroblasts, suggesting that big-h3 expression is
reduced during the malignant transformation of this cell type
[15]. This is supported by experiments with Chinese ham-
ster ovary (CHO) cells, in which transfection of a big-h3
expression plasmid led to a marked decrease in the ability of
these cells to form tumors in nude mice [3].
In epithelial cells, TGF-hs usually exert strong growth
inhibitory effects [16]. However, all three TGF-h ligands are
overexpressed in pancreatic cancer, and that overexpression
is associated with decreased patient survival following
tumor resection [17]. Furthermore, expression analysis of
the receptors has revealed that the type II and type I TGF-h
signaling receptors are also present in pancreatic cancer
[18,19], raising the possibility that TGF-hs may act in an
autocrine manner in this malignancy to promote tumor
growth. However, these cancer cells have lost their ability
to respond to the growth suppressive effects of TGF-hs
because of Smad4 mutations [20], decreased TGF-h recep-
tor type I (ThRI) expression in a subgroup of patients
[21,22] and overexpression of the TGF-h signaling inhib-
itors Smad6 and Smad7 [23,24]. Therefore, it has been
difficult to demonstrate convincingly that TGF-hs act in an
autocrine manner in pancreatic cancer. Since big-h3 is a
downstream target of TGF-h1, in the present study, we
examined the effects of TGF-h1 on big-h3 expression in
cultured pancreatic cancer cells in relation to their Smad4
status, and determined whether big-h3 is present in human
pancreatic tissues. We now show that TGF-h1 is able to
induce big-h3 in pancreatic cancer cell lines, irrespective of
whether Smad4 is mutated or not, and that big-h3 is over-
expressed in pancreatic cancer cells in vivo.
2. Methods
2.1. Cell culture
Human pancreatic cancer cells were routinely grown in
DMEM (PANC-1, MIA-PaCa-2) or RPMI (ASPC-1,
CAPAN-1, T3M4) supplemented with 10% heat-inactivated
FCS, 100 U/ml penicillin, 100 Ag/ml streptomycin, and 2
mM L-glutamine. Cells were maintained at 37 jC in a humid
chamber with 5% CO2 and 95% air atmosphere. For TGF-
h1 experiments, subconfluent cells were incubated over-
night in serum-free medium (containing 0.1% BSA, 5 Ag/ml
transferin, 5 ng/ml sodium selenite, and antibiotics), and
subsequently incubated with 1 nM of TGF-h1 for the
indicated time. Cells were then harvested for RNA extrac-
tion. ASPC-1, CAPAN-1, PANC-1, and MIA-PaCa-2
human pancreatic cell lines were obtained from ATCC
(Rockville, MD, USA). T3M4 human pancreatic cell lines
were a gift from Dr. R.S. Metzgar (Durham, NC, USA).
TGF-h1 was a gift from Genentech, Inc. (South San
Francisco, CA, USA).
2.2. Probe synthesis for Northern blot analysis
A fragment of human big-h3 cDNAwas amplified by RT-
PCR and subcloned into the pGEM-T Easy vector (Promega
Biotechnology, Madison, WI, USA) according to the man-
ufacturer’s instructions. The identity of the cDNA fragments
was confirmed by sequence analysis using the dye terminator
method (ABI 373A, Perkin Elmer, Rot Kreuz, Switzerland).
The mouse 7S cDNA probe that cross-hybridizes with
human 7S and the human PAI-1 cDNA probe were generated
as reported previously [24]. For Northern blot analysis, the
probes were radiolabeled with 32P-dCTP (Du Pont Interna-
tional, Regensdorf, Switzerland) using a random primer
labeling system (Roche Diagnostic Ltd., Rotkreuz, Switzer-
land). For in situ hybridization, digoxigenin-labeled big-h3
cRNA sense and antisense probes were generated using the
Ribomax System (Promega Biotechnology) and the appro-
priate polymerases [24].
2.3. Northern blot analysis
Following electrophoresis of total RNA in a 1.2%
agarose/1.8 M formaldehyde gel, RNA was electrotrans-
ferred onto nylon membranes (Gene Screen, Du Pont,
Boston, MA, USA) and cross-linked by UV irradiation.
The filters were then prehybridized for 5 h at 42 jC and
hybridized for 20 h at 42 jC in the presence of the radio-
labeled cDNA probes for big-h3. Blots were then rinsed
twice with 2 SSC at 50 jC and washed twice with 0.2
SSC/2% SDS at 55 jC for 10 min. All blots were exposed
Table 1
Summary of TGF-h receptor expression, Smad4 mutations and effects of
TGF-h1 on cell growth and PAI-1 and big-h3 expression in pancreatic
cancer cell lines
ASPC-1 CAPAN-1 MIA-PaCa-2 PANC-1 T3M4
ThRI [22] + + + + + + +
ThRII [22] + + +  + + ++
Smad4 [26] mutated mutated wild type wild type wild type
Growth [22] 0 0 0  0
PAI-1 induction 0 0 0 + 0
big-h3 induction 0 + 0 + 0
Expression of ThRI, ThRII as described previously [22]. Symbols: low (+),
moderate (++), high (+++) expression by Northern blotting. Growth
responsiveness to TGF-h1 as described previously [22]. Symbols: no TGF-
h1 responsiveness (0); weak to moderate ( ) growth inhibition by TGF-
h1. Induction of PAI-1 and big-h3 mRNA expression was determined by
Northern blot analysis. Symbols: no induction (0), moderate to strong
induction (+).
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at  80 jC to Kodak BioMax films with Kodak intensifying
screens, and the intensity of the radiographic bands was
quantified by video image analysis, using the Image-Pro
plus software (Media Cybernetics, Silver Spring, MD,
USA). To verify equivalent RNA loading on Northern blot
membranes, filters were rehybridized with the 7S cDNA
probe, as reported previously [24].
2.4. Patients and tissue collection
Normal pancreatic tissue samples were obtained through
an organ donor program from 11 individuals who were free
of any apparent disease. The median age of the organ donors
was 34.8 years, with a range of 14 to 52 years. Pancreatic
cancer tissue samples were obtained from 27 pancreatic
cancer patients (9 female and 18 male, median age 69.6
years) undergoing pancreatic resection. Freshly removed
tissue samples were fixed in paraformaldehyde solution
for 12 to 24 h and paraffin-embedded for in situ hybrid-
ization. Tissue samples for RNA extraction were immedi-
ately snap frozen in liquid nitrogen upon surgical removal in
the operating room and maintained at  80 jC until use. All
studies were approved by the Human Subjects Committee of
the University of Bern.
2.5. In situ hybridization
The tissue sections (4 Am) were deparaffinized, dehy-
drated, and incubated in 0.2 M HCl for 20 min. The sections
were treated with proteinase K (50 Ag/ml) for 15 min at 37
jC. Following post-fixation with 4% paraformaldehyde in
phosphate-buffered saline (PBS) for 5 min, the samples
were prehybridized at 60 jC for 2 h in 50% formamide (v/
v), 4 SSC, 2 Denhardt’s solution and 250 Ag/ml RNA.
Hybridization was performed overnight at 60 jC in 50% (v/
v) formamide, 4 SSC, 2 Denhardt’s solution, 500 Ag/
ml RNA and 10% dextran sulfate (w/v). The final concen-
trations of the digoxigenin-labeled probes were approxi-
Fig. 1. (a) Effects of TGF-h1 on PAI-1 and big-h3 levels. Cells were serum-starved for 12 h and incubated in the absence (0 h) or presence of 1 nM TGF-h1 for
the indicated time. Northern blot analysis of total RNA (20 Ag/sample) was performed with 32P-labeled PAI-1, big-h3 and 7S cDNA probes. (b) Bar graph of
two experiments. The ODbig-h3/OD7S and ODPAI-1/OD7S at 0 h were set to 1.
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mately 0.5 ng/Al. After hybridization, the sections were
washed and treated with RNase. The samples were then
incubated with an anti-digoxigenin antibody conjugated
with alkaline phosphatase (1:500). For color reaction, 5-
bromo-4-chloro-3-indolyl phosphate and nitro-blue-tetrazo-
lium (Sigma, Buchs, Switzerland) were used. For control
experiments, the slides were incubated with RNase or with
the corresponding sense probes. Pretreatment of the slides
with RNase abolished the hybridization signals produced by
the antisense probe. Furthermore, incubation with the sense
probe failed to produce specific in situ hybridization signals.
3. Results and discussion
Cultured pancreatic cancer cell lines are usually resistant
to the growth inhibitory effects mediated by TGF-h1
[22,25]. In the present study, we utilized five pancreatic
cancer cell lines (ASPC-1, CAPAN-1, MIA-PaCa-2, PANC-
1, and T3M4) to assess whether TGF-h1 induces big-h3
expression in these cells (Table 1). We have previously
shown that of those five pancreatic cancer cell lines, only
PANC-1 is growth inhibited by TGF-h1, and that this cell
line expresses ThRI and ThRII and possesses a normal
Smad4 gene [22,26]. ASPC-1 and CAPAN-1 cells are
resistant towards the growth inhibitory effects of TGF-h1
due to Smad4 mutations [26], T3M4 cells are resistant
because they underexpress ThRI [21], whereas MIA-
PaCa-2 cells are resistant due to loss of ThRII expression
[27]. In agreement with previous observations, we could
demonstrate that TGF-h1 induced PAI-1 in a time-depend-
ent manner in PANC-1 cells, but not in the other cell lines
(Fig. 1). TGF-h1 also induced big-h3 mRNA expression in
PANC-1 and CAPAN-1 cells in a time-dependent manner
(Fig. 1). In contrast, TGF-h1 did not significantly alter big-
h3 expression levels in the other three cell lines (data not
shown).
The ability of TGF-h1 to induce big-h3 expression in
CAPAN-1 cells that harbor Smad4 mutations [26] points to
an Smad4-independent mechanism for this induction.
Indeed, there is growing evidence that under some circum-
stances and in some cells, TGF-h signaling might be
mediated in the absence of wild-type Smad4. Thus, in
BxPc-3 pancreatic cancer cells, TGF-h1 exerts growth
inhibitory effects despite the fact that this cell line has a
deleted Smad4 gene [25]. In addition, in VACO-235 colon
cells that harbor Smad4 mutations, TGF-h1 is still capable
of exerting strong growth inhibitory effects [28]. These
results collectively suggest that there is a non-Smad4-
dependent pathway for TGF-h-mediated signaling.
In addition, our results that TGF-h1 induces big-h3
expression but not PAI-1 expression in CAPAN-1, whereas
in PANC-1 TGF-h1 induces the expression of both genes,
points to a dissociation of the TGF-h signaling pathway.
This observation is in agreement with previous reports
demonstrating that the expression of a truncated ThRII or
a mutant ThRI does not attenuate TGF-h1-mediated induc-
tion of PAI-I, but does render Mv1Lu cells resistant to the
antiproliferative effects of TGF-h1 [29]. In addition, tran-
sient overexpression of a mutated Smad3 protein blocks the
antiproliferative effects of TGF-h1 in Mv1Lu cells, while
still allowing for activation of PAI-I transcription [30].
Similarly, in pancreatic cancer cells, overexpression of
Smad6 or Smad7 renders these cells insensitive to the
growth inhibitory effects of TGF-h1, while still allowing
for the induction of PAI-1 [23,24]. Collectively, these data
suggest that there are divergent pathways of TGF-h signal-
ing.
Since we observed TGF-h1-induced big-h3 expression
in cultured pancreatic cancer cell lines, we next examined
whether big-h3 is expressed in human pancreatic cancers in
vivo. Therefore, 11 normal human pancreas samples and 27
human pancreatic cancer samples were investigated by
Northern blot analysis. The big-h3 mRNA transcript was
detected at moderate to strong levels in almost all pancreatic
cancer samples, but was found at weak levels in normal
pancreas samples. Densitometirc analysis indicated that
there was a 32.4-fold increase in big-h3 mRNA levels in
pancreatic cancer tissues in comparison to normal controls
Fig. 2. Northern blot analysis of big-h3 mRNA in human pancreatic tissues.
(a) Total RNA (20 Ag) isolated from normal and cancerous pancreases and
five pancreatic cancer cell lines was subjected to Northern blot analysis and
probed with the 32P labeled big-h3 cDNA. The blot was subsequently
rehybridized with a 7S cDNA probe to verify equivalent RNA loading. (b)
Densitometry of the Northern blots. Relative big-h3 mRNA expression was
calculated as ODbig-h3/OD7S for each sample, and the fold increase over the
mean in the normal pancreatic tissues was calculated. The mean in the
normal samples was set to 1.
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(Fig. 2b). Altogether, 26 of 27 pancreatic cancer samples
expressed big-h3 levels that clearly exceeded the mean
expression level in the normal samples.
To investigate the exact site of big-h3 mRNA expression
in human pancreatic cancer samples, in situ hybridization
was carried out next. The big-h3 mRNA in situ hybrid-
ization signal was intense in the cytoplasm of cancer cells
(Fig. 3C,D). In contrast, in the normal pancreas, big-h3
mRNA signals were weakly present only in a few acinar and
ductal cells (Fig. 3A,B). Previously, we have shown that
human pancreatic cancers overexpress all three mammalian
TGF-h isoforms [17]. Since our cell culture experiments
indicate that TGF-h1 can up-regulate big-h3 even in the
presence of Smad4 mutations, taken together, these obser-
vations suggest that up-regulation of big-h3 expression in
vivo may be due, in part, to autocrine and paracrine effects
of TGF-hs derived from the cancer cells.
The potential role of big-h3 in pancreatic cancer is not
known. Since big-h3 is thought to be involved in cell
attachment to the ECM, thereby influencing cell adhesion
[2,31], it is possible that increased levels of big-h3 in
pancreatic cancers influence cell adhesion and invasion of
pancreatic cancer cells in vivo. Although further functional
studies are required to address this question, the observation
that big-h3 is strongly induced by TGF-h1 in some pancre-
atic cancer cells, irrespective of their Smad4 mutation status,
and that big-h3 is overexpressed in pancreatic cancer cells,
points to a potentially important autocrine loop that has the
potential to contribute to the pathobiology of this disease.
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